Commissioned by a Canadian company, Livingstone ventures has set up an R&D and production line for producing natural psilocybin in the Netherlands.
Psilocybin is a non-addictive psychedelic substance found in specific types of mushrooms.
Natural psychedelics have been used for thousands of years in various cultures worldwide. When psilocybin is administered under controlled conditions in a clinic, with the help of trained therapists can help people get rid of psychological symptoms such as depression, anxiety, and addictions.
Althena’s proposition consists of psilocybin developed and produced entirely in the Netherlands, with high-quality agricultural and pharmaceutical technology. In it, our team of experienced entrepreneurs and academics collaborate with renowned, fully certified R&D laboratories.
The first phase starts with an R&D process in which IP (intellectual property) is developed, and the medicinal (EU-GMP) final product is made following the highest certification standards. For this phase, which lasts 24 months, we are working with specialized partners with the necessary licenses from the Ministry of Health.
The commercial scale-up, which will use the IP, knowledge, and experience from the R&D phase, will start after about 18 months. The company aims to become a market leader in this early-stage medication based on natural psilocybin. The initial focus is on the North American market to which the team has access and is now active.
